Цитогенетический и молекулярный ответ – ранние маркеры эффективности терапии Гливеком больных Ph+ хроническим миелолейкозом


А.Г. Туркина, Е.Ю. Челышева

Цитогенетический и молекулярный ответ - ранние маркеры эффективности терапии Гливеком больных Ph+ хроническим миелолейкозом
Появление препарата Гливек (иматиниба мезилат) коренным образом изменило современный подход к лечению хронического миелолейкоза (ХМЛ). Высокая эффективность лечения этим препаратом привела к изменению прогностического значения некоторых клинических характеристик, которые ранее имели значение для прогнозирования течения ХМЛ. Показано, что одним из самых важных прогностических факторов для выживаемости является цитогенетический и молекулярный ответ на лечение Гливеком. В статье приводятся результаты последних международных исследований о роли цитогенетического и молекулярного ответа для прогнозирования течения ХМЛ, а также данные о возможности и частоте цитогенетического ответа при назначении Гливека в поздней хронической фазе и фазе акселерации. Рассматриваются и другие факторы, влияющие на прогноз эффективности лечения ХМЛ.

Литература






  1. Kantarjian HM, Talpaz M, O’Brien S, et al. Imatinib mesylate for Philadelphia chromosome-positive chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.Clin Cancer Res 2002;8:2177–87.
  2. О’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994–1004.
  3. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collabo-rative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998;90:850–8.
  4. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645–52.
  5. Туркина А.Г., Хорошко Н.Д., Дружкова Г.А. и др. Эффективность терапии иматиниб мезилатом (гливеком) в хронической фазе миелолейкоза // Терапевтический архив 2003. Т. 75. № 8. С. 62–67.
  6. Лория С.С., Курова Е.С., Семочкин С.В., Туркина А.Г. и др. Эффективность и безопасность терапии иматиниб мезилатом (гливеком) больных хроническим миелолейкозом в фазе акселерации // Вопросы гематологии, онкологии и иммунопатологии в педиатрии. 2002. Т. 1. № 2. С. 66–67.
  7. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosi kinase inhibitor for chronic myeloid leukaemia. J Clin Invest 2000; 105:3–7.
  8. Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 1997;63:125–30.
  9. Rowley JD. A new consistent chromosomal abnomality in chronic myelogenous leukemia giemsa starting. Nature 1973;243:290–303.
  10. Gordon MY. Cellular and molecular mechanisms in chronic myeloid leukemia: biology and treatment. Br J Haematol 1996;95:10–20.
  11. Druker BJ, Talpaz M, Debra J, et al. Efficacy and safety of specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia). New england J Med 2001;344:1031–7.
  12. Deininger MV, Goldman GJ, Lydon N, Melo JV. The tyrosine Kinese inhibitor CGP571148 B selectivly ingibits the grouth of BCR-ABL positive cells. Blood 1997;90:3691–8.
  13. Kantarjian HM, Smith T, O’Brien S, et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-a therapy. Ann Intern Med 1995;122:254–61.
  14. Savage DG, Szydlo RM, Chase A, et al. Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse. Br J Haematol 1997;99:30–5.
  15. Talpaz M, Kautarjian HM, Me Credie KB, et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986;314:1065–9.
  16. Kantarjian HM, O’Brien S, Cortes JE, et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003;97:1033–41.
  17. Kantarjian HM, Talpaz M, O’Brien S, et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res 2002;8:2177–87.
  18. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928–37.
  19. Курова Е.С. Клиническая эффективность молекулярно-направленной терапии в фазе акселерации хронического миелолейкоза. Автореф. канд. дис. М., 2003. 21 с.
  20. Cervantes F. On behalf of the IRIS study group. Durability of responses to imatinib in newly diagnosed chronic-phase chronic myeloid leukemia (CML): 24-month update from the IRIS Study. Blood 2003;102:181a.
  21. Kantarjian HM, Talpaz M, O’Brien S, et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res 2002;8:2177–87.
  22. Kantarjian H, Talpaz M, O’Brien S, et al. High-dose imatinib mesylate therapy in newly diag-nosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004;103:2873–8.
  23. Sneed TB, Kantarjian HM, Talpaz M, et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer 2004;100:116–21.
  24. Marin D, Marktel S, Bua M, et al. Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia 2003;17:1448–53.
  25. Kantarjian H, Cortes J. Testing the prognostic model of Marin et al in an independent chronic myelogenous leukemia study group. Leukemia 2004;18:650.
  26. Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988;61:1441–6.
  27. O’Dwyer ME, Mauro MJ, Kurilik G, et al. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 2002;100:1628–33.
  28. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in ‘‘good-risk’’ chronic gran-ulocytic leukemia. Blood 1984;63:789–99.
  29. Sokal JE, Gomez GA, Baccarani M, et al. Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. Blood 1988;72:294–8.
  30. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collabo-rative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998;90:850–8.
  31. Cortes J, Talpaz M, O’Brien S, et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 2003;98: 1105–13.
  32. Martinelli G, Montefusco V, Testoni N, et al. Clinical value of quantitative long-term assessment of bcr-abl chimeric transcript in chronic myelogenous leukemia patients after allogeneic bone marrow transplantation. Haematologica 2000;85:653–8
  33. Hochhaus A, Weisser A, La Rosee P, et al. Detection and quantification of residual disease in chronic myelogenous leukemia. Leukemia 2000;14: 998–1005.
  34. Guo JQ, Lin H, Kantarjian H, et al. Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia 2002;16: 2447–53.
  35. Gabert J, Beillard E, van der Velden VH, et al. Standartisation and quality control studies of “real-time” quantitative reverse transcryptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia. A Europe Against Cancer program. Leukemia 2003;17:2318–57.
  36. Moravkovа et al. Polymerase Chain Reaction Analyses Should Be Used as a Basis for Clinical Decision Making in Patients With Chronic Myelogenous Leukemia. Blood 1999;94:3609–11.
  37. Kurzrock R, Estrov Z, Kantarjian H, Talpaz M. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clin Oncol 1998;16:1526.
  38. Hochhaus A, Reiter A, Saussele S, et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 2000;95:62–6.
  39. Talpaz M, Estrov Z, Kantarjian H, et al. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia: Analysis by polymerase chain reaction of individual colonies. J Clin Invest 1994;94:1381.
  40. Pasternak G, Pasternak L. Persistence of bcr-abl mRNA-expressing cells in long-term cultures established from chronic myeloid leukemic bone marrow or blood. Ann Hematol 1994;68:9.
  41. Cortes J, O’Brien S, Talpaz M, et al. Clinical significance of molecular response in chronic myeloid leukemia after imatinib (Gleevec) therapy: low levels of residual disease predict for response duration. Blood 2003;102:416a (abstract 1513).
  42. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423–32.
  43. Stentoft J, Pallisgaard N, Kjeldsen E. Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 (Glivec) measured by quantative real-time polymerase chain reaction. European Journal of Hematology 2001;67: 302–8.



Бионика Медиа